Core Viewpoint - The company is undergoing a strategic upgrade focusing on glycoscience and cell biology, leveraging its advantages in synthetic biology for health solutions [6] Financial Performance - Total revenue for 2024 is approximately 5.37 billion, a decrease of 11.61% compared to 2023 [2] - Net profit attributable to shareholders is about 174 million, down 70.59% from the previous year [2] - Net profit after deducting non-recurring gains and losses is approximately 107 million, a decline of 78.13% year-on-year [2] - Operating cash flow for the year is around 564 million, a decrease of 19.32% from 2023 [2] - The company's net assets at the end of 2024 are approximately 6.81 billion, a decrease of 1.93% compared to the end of 2023 [2] Profit Distribution - The company plans to distribute a cash dividend of 0.11 yuan per 10 shares (including tax) [3] R&D Investment - Total R&D investment is approximately 466 million, representing an increase of 1.33 percentage points in relation to total revenue [4] Business Operations - Revenue from raw materials is approximately 1.24 billion, showing a year-on-year growth of 9.47% [5] - Medical terminal business revenue is about 1.44 billion, an increase of 32.03% [11] - Revenue from skin science innovation transformation business is approximately 2.57 billion, down 31.62% year-on-year [11] - Basic earnings per share are 0.36 yuan, a decrease of 70.73% compared to the previous year [5] Strategic Focus - The company is focusing on management transformation, including business process restructuring, organizational and talent changes, and performance system reforms [6] - The company aims to continue technological innovation and optimize its business structure to enhance operational efficiency and achieve high-quality development [6] Market Position - The company is a leading player in the global hyaluronic acid market, with significant presence in Europe, Japan, and the Americas [13] - The company is transitioning from rapid growth to high-quality development, increasing investments in synthetic biology and regenerative medicine [13]

上海奉贤正在加快推动"东方美谷产品"向"东方美谷品牌"转变，坚持先进制造业与现代服务业双轮驱 动，打造千亿级美丽健康特色产业集群。 奉贤区委书记袁泉表示，奉贤将聚焦非共识项目、颠覆性技术，鼓励企业积极应用合成生物、人工智能 等技术，持续推动香妆行业跨界融合，让更多高附加值、强竞争力产品从奉贤走向世界，全力打造全球 化妆品创新高地。 与此同时，奉贤将充分发挥自贸区新片区制度优势，用好海关支持上海"东方美谷"化妆品产业高质量发 展的十一条新政，依托化妆品知识产权快速维权中心等功能性平台，加大知识产权保护力度，全方位赋 能香妆行业创新发展。 （文章来源：新华财经） 新华财经上海7月1日电（记者李荣）1日，中国香妆品牌发展大会在上海奉贤"东方美谷"举行。中国香 料香精化妆品工业协会负责人表示，中国香妆行业将在世界舞台展现更强品牌力量。 中国香料香精化妆品工业协会理事长颜江瑛在致辞中指出，中国香妆协会作为面向香料香精和化妆品行 业的唯一"中字头、国字号"行业组织，积极倡导行业的全链协同，全力打造品牌建设生态体系。 她表示，未来，中国香妆行业要在研发创新、文化传承、可持续发展、品牌建设四大维度上，以更高标 准加强自身建设 ...

Core Viewpoint - The article discusses the significant investment by Zhong Shanshan in Jinbo Biological, a company specializing in recombinant collagen products, highlighting the potential for growth in the beauty and medical aesthetics industry [4][5][20]. Group 1: Investment Details - Jinbo Biological announced two transactions, including introducing Yangshengtang as a strategic investor and transferring shares from founder Yang Xia to Hangzhou Jiushi, totaling an investment of 3.4 billion yuan [4][7]. - The strategic investment from Yangshengtang will involve issuing up to 717.57 million shares, potentially raising 2 billion yuan, marking the largest cash increase in the history of the Beijing Stock Exchange [7]. - After the transactions, Zhong Shanshan will hold a 10.58% stake in Jinbo Biological, making him the second-largest shareholder after Yang Xia [10]. Group 2: Company Background - Jinbo Biological, founded by Yang Xia, focuses on recombinant human collagen products and has achieved a market value of 40 billion yuan [5][16]. - The company’s main products include various medical devices and functional skincare products based on type A recombinant human collagen [16]. - Jinbo Biological's core product, the injectable recombinant type III human collagen, has been widely adopted, with over 2 million applications across approximately 4,000 medical institutions [16]. Group 3: Market Dynamics - The medical aesthetics industry, particularly recombinant collagen, is experiencing rapid growth, with Jinbo Biological reporting a revenue of 1.443 billion yuan in 2024, a year-on-year increase of 84.92% [17]. - The gross profit margin for Jinbo Biological reached 92%, surpassing that of leading companies like Kweichow Moutai [17]. - The article notes that the beauty industry is characterized by high repeat purchase rates, making it a lucrative market for investors [22].

Core Viewpoint - The article emphasizes the importance of biomanufacturing as a key focus for enhancing economic competitiveness in various countries, including China, which is advancing its manufacturing capabilities through initiatives like green manufacturing and intelligent manufacturing [1]. Group 1: Event Overview - The Fourth Synthetic Biology and Green Biomanufacturing Conference (SynBioCon 2025) will be held from August 20-22 in Ningbo, Zhejiang, focusing on the integration of AI and biomanufacturing [1]. - The conference aims to explore the development trends of the biomanufacturing industry during the 14th Five-Year Plan period, highlighting innovative technologies and products that will sustain the industry's vitality [1]. Group 2: Organizers and Highlights - The conference is organized by Ningbo Detaizhong Research Information Technology Co., Ltd. (DT New Materials) and co-organized by Ningbo Meisai Biological Engineering Co., Ltd. [2]. - Key highlights include forums on biomanufacturing trends, youth innovation sharing, project roadshows, and participation from leading enterprises, top universities, and investment institutions [4]. Group 3: Agenda and Special Activities - The first day features a closed-door high-level seminar focusing on the development trends and growth points of biomanufacturing, with 30 industry leaders and experts invited [7]. - The second and third days will include a macro forum on biomanufacturing, covering the overall trends and progress in the industry [10]. Group 4: Specialized Forums - Specialized forums will cover topics such as green chemicals and new materials, AI in biomanufacturing, future food and agriculture, and beauty raw materials [11]. - The forums will discuss various aspects of biomanufacturing, including the development of bio-based chemicals, green manufacturing technologies, and the application of AI in industrial processes [11]. Group 5: Project Roadshows and Talent Engagement - The conference will feature project roadshows aimed at connecting head parks and investment institutions with innovative biomanufacturing projects [10]. - A youth forum will be held to discover potential teams and technologies in biomanufacturing, providing a platform for efficient talent and collaboration exchanges [10].

Group 1: Event Overview - The 2025 Beijing Changping Life Science Forum will be held from July 5 to July 7, featuring a "1+6+1+N" format, including one opening ceremony and main forum, six parallel forums, one special exhibition, and multiple closed-door seminars and investment activities [1][4] - The forum aims to create a high-end dialogue platform in the life sciences field, gathering top scientists and industry leaders to discuss cutting-edge scientific issues and industry development trends [4][5] Group 2: Industry Growth and Achievements - Beijing's pharmaceutical and health industry reached a scale of 1.06 trillion yuan in 2024, with 436 large-scale pharmaceutical enterprises generating an output value of approximately 185 billion yuan [2] - The Changping District's pharmaceutical health industry has seen an average annual growth rate of over 8% in the past three years, with a projected revenue of 104 billion yuan in 2024, representing a year-on-year growth of 14.3% [7] Group 3: Innovation and Development - Beijing has approved four innovative drugs and seven innovative medical devices this year, with a total of 79 innovative medical devices approved, accounting for nearly one-quarter of the national total [2][3] - The district has established 27 national-level green factories and 20 advanced intelligent factories, with a focus on digital transformation in the pharmaceutical industry [3] Group 4: Collaborative Efforts - The forum will integrate with the National Pharmaceutical Industry Information Annual Conference to promote the fusion of academic and industrial resources, enhancing innovation and development in the pharmaceutical sector [5][6] - The Changping District is developing an International Medical Device City, which will serve as a model for industry development, showcasing advanced medical equipment and technologies [8]

北京未来科学城管委会副主任，昌平区政府党组成员、副区长赵仕伟26日在新闻发布会上介绍，今年论 坛将采用"1+6+1+N"模式，即1场开幕式及主论坛，6场平行论坛，1场专题展览，多场闭门研讨会、行 业招商推介及投资考察活动，涵盖行业交流、产业对接、政策发布等多个维度。 据介绍，今年论坛有三个特点：一是两会融合，开创协同新模式。联合中国医药工业信息中心，与全国 医药工业信息年会共同举办，两会融合促进前沿科技创新理念与百强医药工业企业资源交融，积极推动 医药产业创新发展，为医药行业的转型升级注入强大动力。 来源：中国新闻网 中新网北京6月26日电 (记者 吕少威)2025北京·昌平生命科学论坛将于7月5日至7日在北京市昌平区石油 科技交流中心举办，涵盖行业交流、产业对接、政策发布等多个维度，上百名演讲嘉宾齐聚一堂，共议 科技创新培育新质生产力，为医药健康创新发展提供新思路、新启示。 三是突出实效，提升产业影响力。聚焦前沿技术、医疗器械、AI+药械、合成生物、美丽健康等赛道， 集中呈现昌平医药创新成果，推动科研机构间科技合作对话，广泛邀请国际、国内科技组织及全球科学 家、企业家、投资人等参与，链接全球创新智慧、搭建交 ...

2'-FL：母乳关键成分，赋能健康营养 作为母乳中含量最高（约30%）的人乳寡糖，2'-FL具有显著的营养与医学价值：促进婴幼儿生长发育及认知能力；增强 免疫力，抗病毒、抗过敏；调节肠道菌群平衡。其应用已覆盖多国婴幼儿配方奶粉，是极具潜力的新型营养强化剂。 未来食品&农业 | 柯泰亚 关于柯泰亚 【SynBioCon】 获 悉 ， 柯泰亚生物科技（上海）有限公司（以下简称"柯泰亚"）宣布，其自主研发的母乳低聚糖 （HMO）核心产品 2'-岩藻糖基乳糖 (2'-FL) 正式通过美国食品药品监督管理局 (FDA) 的GRAS (一般认为安全， Generally Recognized As Safe) 认证。 2025年初柯泰亚向FDA提交了关于2'-FL作为食品配料的申请，2025年6月18日收到FDA的"No Question Letter"， 确认柯泰亚2'-FL可作为食品添加剂应用于婴儿配方奶粉、儿童食品及传统食品及饮料 。此举标志着柯泰亚成为国内少数 获得该认证的本土企业，其研发创新、生产质量与安全管控体系获得国际权威认可。 此次认证是柯泰亚凭借自主知识产权进军全球HMO市场的重要突破。获得FDA GR ...

Core Viewpoint - The article emphasizes the importance of biomanufacturing as a key focus for enhancing economic competitiveness in various countries, including China, which is advancing its manufacturing capabilities through initiatives like green manufacturing and intelligent manufacturing [1]. Group 1: Event Overview - The Fourth Synthetic Biology and Green Biomanufacturing Conference (SynBioCon 2025) will be held from August 20-22 in Ningbo, Zhejiang, focusing on the integration of AI and biomanufacturing [1]. - The conference aims to explore the development trends of the biomanufacturing industry during the 14th Five-Year Plan and identify innovative technologies and products that can sustain the industry's vitality [1]. Group 2: Organizing Institutions - The conference is organized by Ningbo Detai Zhongyan Information Technology Co., Ltd. (DT New Materials) and co-organized by Ningbo Meisai Biological Engineering Co., Ltd. [2]. Group 3: Highlights of the Conference - The conference will feature forums and closed-door activities to gain insights into the development trends of biomanufacturing during the 14th Five-Year Plan, exploring new products, technologies, and collaborations [4]. - There will be over 100 financing project roadshows to discover new cooperation opportunities [4]. - Key industry players, top universities, and capital from various sectors will gather to discuss advancements in biomanufacturing [4]. Group 4: Special Activities and Agenda - The first day will include a closed-door seminar focusing on the development trends and growth points of biomanufacturing, inviting 30 industry leaders and experts for in-depth discussions [7]. - The second and third days will feature a macro forum on biomanufacturing, covering the development trends and progress of policies related to the industry [10]. Group 5: Specialized Forums - The conference will host specialized forums on various topics, including green chemicals and new materials, AI in biomanufacturing, future food and agriculture, and beauty raw materials [11]. - Each forum will address specific themes such as the development of bio-based chemicals, green manufacturing technologies, and the application of AI in biomanufacturing processes [11].

2025年夏季达沃斯论坛6月24日到26日在天津举行。论坛期间，多位跨国企业负责人表示，中国庞大的 市场和新产业新技术的快速发展，将为跨国企业在中国的发展提供源源不断的动能。与会嘉宾表示，中 国拥有广阔的市场和强大的科研能力，这些将坚定跨国企业在中国投资的信心。随着中国在人工智能、 人形机器人等领域的快速发展，跨国企业也找到了与中国企业合作的新方向。此外，脑机接口、合成生 物等未来产业在中国的快速布局，也让跨国企业期待在相关领域能有更多合作。（央视新闻） ...

Core Viewpoint - The article discusses the announcement of a project by Ningxia Zhongke Biological New Materials Co., Ltd. to produce 110,900 tons of bio-fermentation products annually, highlighting the company's technological upgrades and production capabilities in the bio-manufacturing sector [1]. Project Overview - Project Name: Annual production of 110,900 tons of bio-fermentation products - Construction Unit: Ningxia Zhongke Biological New Materials Co., Ltd. - Nature of Construction: Technological upgrade - Industry Category: C2710 Chemical raw materials and pharmaceutical manufacturing - Investment: 100.89 million yuan - Location: Shizuishan Economic and Technological Development Zone - Land Area: 387,309.18 m², utilizing existing facilities without new land acquisition [2]. Construction Scale - The project includes four flexible production lines: 1. **Long-chain dicarboxylic acid production line**: Annual capacity of 18,000 tons, producing various dicarboxylic acids [3]. 2. **Bio-fermentation functional products production line**: Annual capacity of 5,100 tons, including D-chiro-inositol, coenzyme Q10, and DHA algae oil [4]. 3. **Bio-food production line**: Annual capacity of 63,000 tons, producing calcium propionate and L-malic acid [5]. 4. **Amino acid products production line**: Annual capacity of 24,800 tons, producing various amino acids [6]. Technological Upgrade Scope - The upgrade encompasses fermentation workshops, extraction workshops, refining workshops, drying workshops, liquid bio-fertilizer workshops, tank areas, and power centers [7]. Company Background - Ningxia Zhongke Biological New Materials Co., Ltd. was established on June 2, 2017, with a registered capital of 1.3 billion yuan. The company is involved in the production of feed additives, food additives, fertilizers, and bio-based materials [8]. Financial Performance - The company reported revenue of 345 million yuan and a net loss of 539 million yuan during the reporting period. To address its debt crisis, the company entered pre-restructuring in May 2024, with government support extended until the end of 2024 [9]. - In the first quarter of 2025, the company achieved total revenue of 93.82 million yuan, a year-on-year increase of 74.08%, but still reported a net loss of 64.08 million yuan [11].